Pramipexole
- Generic Name
- Pramipexole
- Brand Names
- Mirapex, Mirapexin, Sifrol, Pramipexole Teva, Oprymea
- Drug Type
- Small Molecule
- Chemical Formula
- C10H17N3S
- CAS Number
- 104632-26-0
- Unique Ingredient Identifier
- 83619PEU5T
- Background
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is one of the most common neurodegenerative disorders and...
- Indication
This drug is indicated for the symptomatic treatment of Parkinson’s disease . This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) .
- Associated Conditions
- Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
- Associated Therapies
- -
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
- Conditions
- Interventions
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 330
- Registration Number
- NCT00335166
- Locations
- 🇺🇸
418, Albany, New York, United States
🇮🇳336, Mumbai, India
🇵🇱371, Kalisz, Poland
Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 535
- Registration Number
- NCT00321854
- Locations
- 🇺🇸
248.595.0102 Boehringer Ingelheim Investigational Site, Traverse City, Michigan, United States
🇺🇸248.595.0103 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇮🇹248.595.39012 Azienda Ospedaliera Pisana- Università degli Studi di Pisa, Pisa, Italy
Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
- First Posted Date
- 2006-03-01
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 296
- Registration Number
- NCT00297778
- Locations
- 🇦🇹
248.596.43001 Boehringer Ingelheim Investigational Site, Innsbruck, Austria
🇦🇹248.596.43005 Boehringer Ingelheim Investigational Site, Linz, Austria
🇦🇹248.596.43003 Boehringer Ingelheim Investigational Site, Graz, Austria
Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients
- Conditions
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 346
- Registration Number
- NCT00275457
- Locations
- 🇦🇹
Univ.-Klinik für Neurologie, Innsbruck, Austria
🇸🇪Boehringer Ingelheim Investigational Site, Örebro, Sweden
🇦🇹Confraternität Privatklinik, Wien, Austria
Pramipexole Conversion to Ropinirole Controlled Release (CR)
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2012-08-24
- Lead Sponsor
- Rajesh Pahwa, MD
- Target Recruit Count
- 61
- Registration Number
- NCT00275275
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease
- Conditions
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 208
- Registration Number
- NCT00240409
- Locations
- 🇨🇳
First Hospital of Beijing University, Beijing, China
🇨🇳Beijing Hospital, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
Dose Finding Study of Pramipexole (Sifrol) in Patients With Idiopathic Restless Legs Syndrome (RLS)
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 109
- Registration Number
- NCT00239486
- Locations
- 🇫🇮
NEURO, Helsinki, Finland
A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 224
- Registration Number
- NCT00152958
- Locations
- 🇩🇪
Clinpharm International GmbH & Co. KG, Berlin (Hellersdorf), Germany
🇩🇪emovis GmbH, Berlin, Germany
🇩🇪Paracelsus-Elena-Klinik, Kassel, Germany
Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 58
- Registration Number
- NCT00144209
- Locations
- 🇨🇭
Boehringer Ingelheim Investigational Site, Zurzach, Switzerland
Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2014-03-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 246
- Registration Number
- NCT00144300
- Locations
- 🇺🇸
248.538.00010 Boehringer Ingelheim Investigational Site, New York, New York, United States
🇺🇸248.538.00013 Boehringer Ingelheim Investigational Site, Atlanta, Georgia, United States
🇺🇸248.538.00006 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.